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Abstract HSV-I protease is involved in virus maturation. It is 
autoproteolytic and processed from a larger precursor. We have 
analysed the autoproteolysis of UL26 ORF and shown by in 
vitro-coupled transcription and translation that the UL26 en- 
coded protein is processed, leading to the accumulation of its 
N-terminal domain. The deletion of the residues 245-248 in UL26 
ORF abolishes the N-terminal cleavage but not the C-terminal 
processing. Deletion of the 3' end of UL26 prevents production 
of the mature protease. These results strongly suggest that 
autoproteolysis achieved in a defined order. 
Key words. HSV-1 protease; UL26 open reading frame; 
Autoproteolysis; In vitro transcription translation 
1. Introduction 
Herpes viruses have a common assembly pathway. Recent 
reports have demonstrated the involvement of a protease, the 
role of which is critical for virus maturation. The same matura- 
tion mechanism was also reported for cytomegalo [1,2] and 
pseudorabies viruses [3] and is suspected to be shared by all 
members of the herpes virus family [1]. The identification and 
characterisation f a herpes simplex virus gene product re- 
quired for encapsidation f viral DNA was first described [4] 
through the isolation of a temperature-sensitive ( s 1201) HSV- 
1 mutant. This mutant fails to encapsidate viral DNA at the 
non-permissive temperature. Protein analyses of full and empty 
capsids howed that full capsids consist of infected cell protein 
35 (ICP 35) while empty capsids consist of unprocessed assem- 
bly protein precursor [5,6]. HSV-1 genome sequencing [7] has 
assigned the coding domain of ICP 35 to the UL26 open read- 
ing frame. It was demonstrated [8] that UL26 contains two 
transcriptional units leading to two proteins sharing amino 
acids. HSV-I UL26 ORF has been shown [9] to encode a 
protease responsible for assembly protein precursor matura- 
tion. Several groups have concluded that the proteolytic activ- 
ity of UL26 ORF is located in the N-terminal part and that two 
cleavages are necessary to produce the mature protease [9 14]. 
A third cleavage site in the catalytic region of the protease 
encoded by human cytomegalovirus UL80 ORF has also been 
identified [2,15]. 
Attempts to identify the proteolytic cleavage sites have been 
reported previously using different approaches. For HSV-1, 
autoprocessing in Escherichia coli by expression of a fusion or 
a non-fusion HSV-1 protease has been described [11,12]. Some 
mutagenesis studies have also been performed to try to identify 
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the residues implicated in the active site [13,14]. The use of 
different protease inhibitors has suggested that HSV-1 protease 
belongs to the serine protease family [13] and more recently 
Ser 129 was shown to be part of the active site [16]. 
In order to characterise the autoprocessing cascade and 
analyse the amino acid requirements for maturation of UL26 
ORF, we have produced the entire protein encoded by UL26, 
the N-terminal of UL26, and the region corresponding to the 
first 329 amino acids of UL26. We demonstrate by in vitro 
transcription and translation that the UL26 encoded protein is 
processed, leading to the accumulation of its N-terminal do- 
main. The deletion of the 4 residues 245-248 in UL26 allowed 
us to confirm the necessity of this sequence for the N-terminal 
cleavage. We also show that the N-terminal cleavage sequence 
is necessary for production of the mature protease but is dis- 
pensable for the C-terminal processing of UL26 ORF. And 
finally the 329 amino acid protein extending from the N-termi- 
nal to 82 amino acids beyond the cleavage site was not able to 
perform the autoproteolysis necessary to release the mature 
protease. These results trongly suggest that autoproteolysis is 
achieved in a defined order. 
2. Material and methods 
2.1. Plasmid construction 
All DNA manipulations were carried out according to standard 
procedures [17]. Restriction enzymes were from New England Biolabs, 
amplification reagents were from Perkin-Elmer Cetus. The coding se- 
quence of the HSV-1 assembly protein precursor (1.9 kb) and of the 
HSV-1 protease (0.74 kb) were obtained by amplification ofpGX142 
(a gift of Dr. V. Preston, MRC Virology Unit, Glasgow, UK) using 
PCR. pGX 142 contains the entire UL26 DNA sequence. Oligonucleo- 
tides corresponding to the 5' and 3' ends of both the protease precursor 
and the protease, with extensions containing restriction sites for clon- 
ing, were synthesised ona 381A Applied Biosystem DNA synthesiser. 
Primer sequences used for PCR amplification were (5' GGGA- 
ATTCAGGAATATAGATCTTATGGAGCCGATGCCCCG 3') and 
(5' TTAAAGCTTAGATCTTCATCAGCGGGCCCCCATCATCTG 
Y) for HSVA construction. For HSVB, the same forward primer 
was used but the reverse primer was (5' TTAAAGCTTAGATCT- 
TCATCACGCCTGGAGGTAGGTGTG Y). PCR reactions were per- 
formed for 30 cycles of 3 min at 95°C, 2 min at 68°C and 1 min at 72 ° C. 
Before amplification, primers were placed for 10 min at 100*C and then 
5 min on ice to avoid primer annealing [18]. The resulting amplification 
products were gel-purified, igested with EcoR1 and HindIII and sub- 
cloned in pBS (Stratagene) linearised with the same ndonucleases. The 
resulting recombinant plasmids were pBSHSVA encoding amino acids 
14535 and pBSHSVB encoding amino acids 1-247 of the protease. 
Sequence analysis of the two plasmids was performed on a 373A Ap- 
plied Biosystem DNA sequencer with the Taq Dyedeoxy Terminator 
Cycle reagents (Applied Biosystems). The amplification conditions 
were adjusted to accomodate the GC-rich content of the DNA and were 
as follows: 1 min at 96°C, 15 s at 65°C and 4 min at 60"C for 25 cycles. 
For in vitro transcription and translation, the BglII fragments from 
pBS recombinant plasmids were inserted in BamHI-digested pSPT18 
vector (Boehringer-Mannheim) giving pSPTHSVA and pSPTHSVB. A 
mutant HSVA construct was produced by replacing the HpaI-ApoI 
fragment in pSPTHSVA by 2 complementary oligonucleotides l ading 
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to pSPTHSVAALQAS. These 2 oligonucleotides are identical to the 
original fragment but without nucleotides corresponding to amino 
acids 245-248 which encode the putative cleavage site LQAS (Fig. 1). 
Plasmid pSPTHSVG encoding residues 1-329 was obtained by remov- 
ing the BamHI-HindIII fragment. The resulting constructs 
pSPTHSVAALQAS and pSPTHSVG were sequenced using the same 
conditions as the original construct. 
2.2. In vitro transcription and translation 
In vitro transcription and translation were performed simultaneously 
by using the TNT-coupled reticulocyte lysate system (Promega). 
Briefly, 5 gg of circular plasmid pSPTHSVA, pSPTHSVB, pSPTHSVG 
or pSPTHSVAALQAS were incubated with 25/11 rabbit reticulocyte 
lysate according to the manufacturer's protocol in the presence ofSP6 
polymerase and 40 ,uCi [35S]methionine at 1000 Ci/mmol (Dupont- 
NEN). A negative control without DNA template, ora positive control 
(supplied by Promega), were performed in parallel. In all assays, the 
final volume was 50 pl and the incubation was for 2 h at 30°C. For 
analysis of the processing ofthe translated proteins, aliquots of 12.5 gl 
were removed at different times during the reaction. In some xperi- 
ments, the transcription/translation reaction mix was further incubated 
at 37°C up to 18 h. After incubation, products of translation were 
resolved on a 12.5% denaturant polyacrylamide g l [19] and analysed 
by autoradiography. 
3. Results and discussion 
3.1. In vitro processing of  HSV-1 protease 
HSV-1 UL26 ORF was obtained by amplification of 
pGX142 and subsequently subcloned into pSPT18 in order to 
transcribe and translate the ORF. Two different constructs, 
pSPTHSVA and pSPTHSVB, were made. pSPTHSVA con- 
tains the entire UL26 ORF while pSPTHSVB encodes the 
N-terminal part of UL26 up to amino acid 247 after which a 
termination codon was inserted (Fig. 1). A similar construct 
coding for residues 1-247 has been used previously in transfec- 
tion and infection experiments [14]. 
Protein products present in the translation mix were analysed 
by gel-electrophoresis at 30 rain intervals. The size of the trans- 
lation products of pSPTHSVA coding for the entire UL26 
ORF varied with time. After 30 min, the first protein product 
of apparent MW 66 kDa was synthesised (Fig, . 2A, lane 4). 
A limited number of lower molecular weight proteins appeared 
with time. Five labelled proteins were detected: 2 migrated to 
around 66 kDa, 2 to 45 kDa and 1 to 30 kDa (Fig. 2A, lanes 
3-6). These labelled proteins were all specific to the transcrip- 
tion and translation of UL26 as they did not appear in either 
the negative or the positive control samples even after pro- 
longed incubation at 37°C. These five proteins correspond to 
the calculated molecular weights of full-length and proteolytic 
products of UL26 ORF, assuming cleavage occurs between 
residues 247-248 and between residues 610-611 resulting in 
proteins of 66,470, 63,881, 39,869, 37,280 and 26,619 Da. When 
the translation mix was incubated at 37°C for more than 2 h, 
the 66 kDa protein disappeared accompanied by a correspond- 
ing increase in the smaller proteins, suggesting that these pro- 
teins represent the final proteolytic products (Fig. 2B, lane 1). 
In vitro transcription/translation of pSPTHSVB, which en- 
codes amino acids 1 247, resulted in the synthesis of a protein 
with a relative gel mobility inferior to 30 kDa within 30 min 
which accumulated over the time period (Fig. 2A, lanes 7-10). 
The relative mobility of this protein is in good agreement with 
the calculated molecular weight (26 619 Da) for amino acids 
1-247 of UL26 ORF. Upon further incubation o additional 
bands appeared but there was an accumulation f the 30 kDa 
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B) Proteins encoded by the DNA constructs: 
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Fig. 1. Schematic maps of the constructions. (A) DNA constructs for 
HSVA, HSVB and HSVG. Numbers refer to the nucleotide sequence, 
l being the first A of the initiating methionine, HSVAALQAS results 
in the replacement of the HpaI-Apo] fragment by 2 synthetic oligonu- 
cleotides. (B) Predicted coding domains of the 4 constructs. Numbering 
refers to amino acid, 1 being the initiating methionine. The difference 
in the coding domain between HSVA and HSVAALQAS is indicated. 
HSVB ends at Ala  247 and HSVG encodes amino acids 1-329. The 
C-terminal cleavage site, V608-N609-A610-S611, is indicated. 
protein (Fig. 2A, lane 10). The translation product of 
pSPTHSVB co-migrates exactly with the shortest protein ob- 
tained from pSPTHSVA coding for the complete UL26 ORF, 
demonstrating that the 30 kDa autoproteolytic product of 
UL26 ORF corresponds to the N-terminal 247 amino acids of 
the precursor protein (Fig. 2A, lanes 6 and 8). This 30 kDa 
protein appears as a doublet in most experiments. Doublet 
bands have been reported and have been characterised individ- 
ually under the name of ICP35c, ICP35d, ICP35e and ICP35f 
[5]. The origin of these doublets is still not clear. It was postu- 
lated that they arose from initiation at Met 1 and Met 1° [8,9]. 
More recently, the region responsible for the doublet formation 
was located between residues 307 and 417 by the use of different 
eDNA constructs and observing the behaviour of the expressed 
proteins by gel-electrophoresis. However, there was no evi- 
dence of a protein doublet formed from the 1-247 construct 
[14]. Under our conditions, a faint band appears under the 
major 30 kDa protein either after the processing of the 635 
residue protein or when the 30 kDa protein is synthetised di- 
rectly from pSPTHSVB (Fig. 2A, lanes 8-10, and Fig. 2B, lane 
2). The two bands appear to be related as they increase in 
parallel. We cannot explain the origin of this additional band. 
It could result from some specific or non-specific proteolysis or 
be a migration peculiarity of HSV-I protease. Prolonged incu- 
bation of the translational reaction mixture of pSPTHSVB does 
not result in any additional processed proteins (Fig. 2B, lane 
2), as has been shown for human cytomegalovirus UL80 ORF 
expressed in E. coli [2]. The third cleavage site in UL80, leading 
to 2 fragments of 13 and 16 kDa, appears to be specific to 
cytomegalovirus protease as no form shorter than 247 residues 
has ever been reported for HSV-I protease. 
Effects of protease inhibitors on the processing of UL26 
ORF have been studied after inhibition of translation by cyclo- 
heximide [13]. In our experiments, we did not stop translation 
in order to visualise the products formed during translation and 
processing of UL26 ORF. Most of the reported translation 
experiments were performed with UL26 ORF and with UL26.5 
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Fig. 2. In vitro transcription a d translation of pSPTHSVA and pSPTHSVB. (A) Lanes: l, negative control; 2, positive control after 2 h of incubation 
at 30°C; 3-6, proteins ynthesised after transcription/translation of pSPTHSVA analysed at time 0, 30, 60, 90 min; 7-10, translational products of 
pSPTHSVB at time 0, 30, 60 and 90 min. (B) Lanes 1 and 2, result of transcription/translation of, respectively, pSPTHSVA and pSPTHSVB after 
an incubation of 22 h at 37°C. The molecular weights are indicated in kDa. Proteins resulting from expression and processing ofUL26 ORF are 
indicated by an arrow. 
ORF which encodes residues 307-635 [8]. Translation of the 
shortest HSV-1 protease corresponding to amino acids 1-247 
has not been reported previously. 
The same type of construct was studied for the HCMV by 
expression in E. coli by radio-pulse-labelling and by coupled 
transcription/translation in bacterial $30 extracts [2]. From that 
study, an autoproteolytic cleavage was clearly demonstrated 
when experiments were performed by radiolabelling in total 
E. eoli cells compared to bacterial $30 extracts. For the simian 
cytomegalovirus [1], trials of transcription/translation of the 
full length protease precursor in a rabbit reticulocyte system did 
not result in autoproteolysis. The conclusion was that matura- 
tion of the protease required an activation step which can occur 
in vivo but not in vitro. In our experiments, UL26 ORF is fully 
processed in vitro in a time-dependent manner. Our experi- 
ments demonstrate that the first cleavage occurs at the 
C-terminus. Following the release of active protease, both 
cleavages occur in parallel, and this is demonstrated by the 
presence of the 2 bands around 45 kDa. Our in vitro expression 
system permits autoproteolytic processing and can be used to 
analyse deletions or modifications that affect these events. 
3.2. Deletion of the N-terminal cleavage site 
Different approaches have been used to identify both cleav- 
age sites in HSV-I protease. Proteolytic fragments of UL26 
expressed in E. coli were identified by N-terminal peptide se- 
quencing [11] and site-directed mutagenesis of the putative N- 
terminal cleavage site (Ala247Arg-Ser248pro) resulted in the ab- 
sence of proteolysis [14]. We approached the question by re- 
moving the entire sequence Leu245-G]n246-Ala247-Ser24S and 
analysing the results of the deletion by in vitro transcription 
and translation. Experiments were carried out in parallel for 
pSPTHSVA and pSPTHSVAALQAS using the same condi- 
tions. When translation products were analysed immediately 
after the reaction, both constructs produced the same labelled 
proteins (Fig. 3A, lane 2 and 7). To investigate he autoproteol- 
ysis of the mutated construct, the same experiment was re- 
peated but the translational mixes were incubated for different 
times at 30°C in parallel with a positive control which was 
treated in the same manner. During incubation, the unmutated 
clone underwent autoprocessing but in the mutated clone only 
the 60 kDa form was formed (Fig. 3A, lanes 1 10). The C- 
terminal cleavage occured but no shorter forms were detected. 
This result is in good agreement with the result found following 
substitution of Ala247-Ser248 byArg-Pro [14] where C-terminal 
cleavage was observed. This means that the protease is still 
active but cannot be completely processed. The fact that the 
protease is active is not surprising since the catalytic domain 
is untouched. Site-directed mutagenesis of Glu jl4 and Glu ~15 
produced an inactive protease [14], and HSV-1 protease la- 
belling allowed the identification of Ser Z29 as part of the active 
site [16]. From our experiments, we can conclude that LQAS 
is the N-terminal cleavage site and is necessary for the process- 
ing of UL26 into its mature form encompassed by residues 
1-247. However, this sequence is not necessary for the C-termi- 
nal cleavage to occur. 
3.3. Deletion of the C-terminal domain 
In an attempt o determine if the presence of only the N- 
terminal cleavage site of the protease was sufficient for matura- 
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Fig. 3. In vitro transcription/translation of pSPTHSVA, pSPTHSVAALQAS and pSPTHSVG. (A) pSPTHSVA and pSPTHSVAALQAS. Lanes 1-5, 
translation products of pSPTHSVA after 0, 30, 60, 90 and 120 min of reaction. Lanes 6-11, translation products of pSPTHSVAALQAS, respectively, 
at time 0, 30,60,90, 120 min and after 16 h (this last incubation was performed at 37°C after the 2 h of transcription/translation at 30°C). Arrows 
indicate the different proteolysis products. (B) In vitro transcription and translation of pSPTHSVG. Lanes 14, translation products of pSPTHSVG 
after 0, 30, 60, 90 and 120 min of reaction. 
tion of the protease, we investigated the behaviour of the first 
329 amino acids. For this experiment, plasmid pSPTHSVG 
was constructed (Fig. 1). Transcription and translation of 
pSPTHSVG were carried out using the same conditions as the 
three other constructs and the results are shown in Fig. 3B. 
Upon incubation from 0 to 2 h, a single protein with a relative 
gel mobility superior to 31 kDa is synthesised. This corresponds 
to the expected molecular weight for HSVG which, upon calcu- 
lation, should be 35,035 Da. One might expect autoproteolysis 
to occur at the intact LQAS site to produce mature HSV-1 
protease but, unexpectedly, no protein co-migrating with 
HSVB is detected even after over-exposure of the gel. The 
absence of processing could be related to the substrate specific- 
ity of the protease. This is unlikely to be the case as the con- 
struct contains 82 residues after the cleavage sequence LQAS. 
Studies using synthetic substrate peptides have shown cleavage 
of a P9-P5' sequence [20]. Maturation of the precursor appears 
to require an initial cleavage at the C-terminal site followed by 
the the N-terminal cleavage. This is in agreement with the result 
obtained with the N-terminal deleted construction where proc- 
essing at the C-terminal site still occurred. The maturation 
appears to be well orchestrated, following a defined succession 
of events. Our results with the 4 constructs suggest that cleav- 
age at the C-terminal end of the precursor is necessary for 
release of the mature protease in the expression system used. 
These results, however, do not preclude the possibility that the 
247-329 tail in HSVG may shield the N-terminal cleavage site. 
Point mutations in the C-terminal cleavage site, for example at 
position 610, would rule out this alternative interpretation a d 
would demonstrate the requirement of C-terminal cleavage for 
release of mature HSV-1 protease. For the cytomegalovirus, the 
terminology maturational (M) site and release (R) site has been 
suggested [1]. Whether an activation step is necessary, as postu- 
lated [1], or whether some post-translational events are neces- 
sary, as suggested [20], remain to be demonstrated. By peptide 
substrate mimics, it was clearly shown that the M and R sites 
were not cleaved with the same efficiency [15]. This difference 
could be a way of regulating the production of the mature 
protease during the virus life cycle. HSV-1 protease isan impor- 
tant potential target for drug design against herpes viruses. An 
understanding of its precise mode of action in vivo and its 
regulation are necessary in order to design potent and effective 
inhibitors of the virus assembly. 
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